Isolated new onset ‘atypical’ optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up

• Published in: Journal of neurology Vol. 263; no. 2; pp. 370 - 379
• Main Authors: Piccolo, L., Woodhall, M., Tackley, G., Juryńczyk, M., Kong, Y., Domingos, J., Gore, R., Vincent, A., Waters, P., Leite, M. I., Palace, J.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.02.2016; Springer Nature B.V
• Subjects: Adolescent; Adult; Antibodies; Aquaporin 4 - immunology; Autoantibodies - blood; Autoantigens - immunology; Child; Child, Preschool; Female; Glycoproteins; Humans; Immunoglobulin G - blood; Male; Medicine; Medicine & Public Health; Middle Aged; Multiple sclerosis; Myelin-Oligodendrocyte Glycoprotein - immunology; Neurology; Neuromyelitis Optica - blood; Neuromyelitis Optica - diagnosis; Neuromyelitis Optica - immunology; Neuroradiology; Neurosciences; Optic Neuritis - blood; Optic Neuritis - diagnosis; Optic Neuritis - immunology; Original Communication; Prognosis; Retrospective Studies; Young Adult; United Kingdom > UK; Neuromyelitis optica; Visual loss; Optic neuritis; MOG-Ab; AQP4-Ab
• ISSN: 0340-5354; 1432-1459
• DOI: 10.1007/s00415-015-7983-1

Severe, recurrent or bilateral optic neuritis (ON) often falls within the neuromyelitis optica spectrum disorders (NMOSD), but the diagnosis can be particularly challenging and has important treatment implications. We report the features, course and outcomes of patients presenting with atypical ON when isolated at onset. We retrospectively analyzed 69 sequential patients referred to a single UK NMO center with isolated ON at onset. Aquaporin-4 antibody (AQP4-Ab) assessment was performed in all patients and IgG1 myelin-oligodenrocyte glycoprotein (MOG-Ab) in AQP4-Ab neg patients. 37 AQP4-Ab positive (AQP4-Ab pos ) and 32 AQP4-Ab negative (AQP4-Ab neg ) patients (8 with MOG-Ab) were identified. The AQP4-Ab neg group included heterogeneous diagnoses: multiple sclerosis (MS), NMO, relapsing isolated ON (RION), monophasic isolated ON and relapsing acute disseminated encephalomyelitis (ADEM)-like syndromes. Compared to AQP4-Ab neg patients, AQP4-Ab pos patients had a worse residual visual outcome from first attack (median VFSS 4 vs. 0, p  = 0.010) and at last assessment (median VFSS 5 versus 2, p  = 0.005). However, AQP4-Ab neg patients with RION also had poor visual outcome. Up to 35 % of AQP4-Ab neg patients developed a LETM and two developed low positivity for AQP4-Ab over time. Eight AQP4-Ab neg patients (25 %) were MOG-Ab positive, covering a range of phenotypes excluding MS; the first ON attack was often bilateral and most had relapsing disease with a poor final visual outcome [VFSS 4, range (0–6)]. In conlcusion, AQP4-Ab positivity is confirmed as a predictor of poor visual outcome but AQP4-Ab neg RION also had a poor visual outcome. Of those without AQP4-Ab, 25 % had MOG-Ab and another 25 % developed MS; thus, MOG-Ab is associated with AQP4-Ab neg non-MS ON.